In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 1.
Figure 1.

Cisplatin mutational signature. Trinucleotide-context mutational spectra shown as (A) raw counts and (B) rate of mutations per million trinucleotides for all MCF-10A (top panel) and all HepG2 (bottom panel) clones combined. In A, the number of mutations per SNS type is shown above the corresponding bars. (C) Pentanucleotide sequence contexts for all samples combined, normalized by pentanucleotide occurrence in the genome. See also Supplemental Figure S2.

This Article

  1. Published in Advance April 9, 2018, doi: 10.1101/gr.230219.117 Genome Res. 28: 654-665

Preprint Server



Current Issue

  1. March 2026, 36 (3)
  1. Current Issue
  1. Alert me to new issues of Genome Research